1. Scrip
  2. >>R&D
  3. >>Clinical Trials

BIO 2021 Notebook: Biogen CEO On Corporate Responsibility

 
• By Scrip Team and Pink Sheet Team

News and views from day four of the BIO Digital annual meeting include the FDA's plans to use carrots not sticks to improve diversity and reflections on how the pandemic has strengthened biopharmaceutical supply chains. 

BIO 2021 Notebook - Day 4

Biogen, Inc. has gotten a lot of criticism about the $56,000-a-year price tag for its new Alzheimer's drug Aduhelm (aducanumab), given that it was granted an accelerated approval by the US Food and Drug Administration based on a surrogate endpoint and the efficacy still needs to be confirmed. Speaking about corporate responsibility at the Biotechnology Innovation Organization (BIO) annual meeting with BIO CEO Michelle McMurry-Heath on 17 June, CEO Michel Vountasos said the company has to do a better job communicating its position to the public.

"The company is taking a position that is very responsible that is yet to be understood out there, and we...

Welcome to Scrip

Create an account to read this article

Already a subscriber?

More from Clinical Trials

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 
• By Andrew McConaghie

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By Manas Mishra

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 
• By Jessica Merrill

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By Kevin Grogan

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

More from R&D

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 
• By Jessica Merrill

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By Kevin Grogan

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

Obesity Beyond GLP-1s: Amylins – The Next Frontier

 
• By Aakash Babu

In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. First on our list – amylin receptor agonists, which analysts expect to grow into a $50bn market opportunity.